Loading...
  • Relapse
  • the occurrence of acute and chronic graft versus host disease, survival, transplantation-related mortality, and relapse rates were compared. (clinicaltrials.gov)
  • While many of these therapies have offered substantial benefit for eradication of primary tumors, the incidence of disease relapse is still a commonly encountered problem that results from residual malignant cells and/or tumor metastases [ 3 , 4 ]. (jcancer.org)
  • T cells are the key effectors of graft-versus-tumor immune responses, highlighted by the efficacy of donor lymphocyte infusions in mitigating disease relapse in certain conditions ( 6 ). (jimmunol.org)
  • efficacy
  • Current work focuses on imparting multi-specificity to CAR T cells and optimizing these receptors to enhance their efficacy when the amount of target (antigen density) is limiting (Majzner et al. (stanford.edu)
  • Leukemia
  • The rationale behind the NST strategy is to induce optimal graft-versus-leukemia (GVL) effects for the elimination of all malignant cells by alloreactive immunocompetent cells from a matched donor as an alternative to standard high-dose myeloablative chemo radiotherapy. (clinicaltrials.gov)
  • clinical
  • Stem cell selection is another technique being studied in clinical trials that can reduce the number of T lymphocytes that a patient receives. (lls.org)
  • Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation: Models in Discovery and Translation, Second Edition once again provides clinical and scientific researchers with a deep understanding of the current research in this field and the implications for translational practice. (elsevier.com)
  • 19 - 23 With advances in the clinical practice of cord blood transplantation, most patients unable to find a fully matched adult donor can identify a partially matched cord blood donor. (aappublications.org)
  • DURHAM, N.C. MARCH 26, 2019 - The potential for stem cells to reduce damage, regenerate tissue and promote functional recovery after a spinal cord injury (SCI) is being tested in several ongoing clinical trials. (stemcellsportal.com)
  • antibodies
  • Humoral immunity can neutralize and eradicate outside microbes and toxins via antibodies produced by B cells [ 24 - 26 ], whereas cellular immunity responds more quickly to eradicate intracellular microbes through recognition of antigens, activation of antigen presenting cells (APCs), activation and proliferation of T cells. (jcancer.org)
  • recipient
  • Randomization was carried out centrally at the International Institute for Drug Development (id2), Brussels, Belgium, and used the minimization method to allocate donor and recipient to allogeneic BMT or PBPCT. (clinicaltrials.gov)
  • immune cells
  • The innate immune cells can release signals which are essential to stimulate responses from both T cells and B cells [ 31 ]. (jcancer.org)
  • Here, microRNAs (miRs) represent an interesting tool since miRs have been recently reported to be an important regulator of various cells, including immune cells such as T cells. (springer.com)
  • A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22 proteins. (stanford.edu)
  • autoimmune
  • [ 7 ] These abnormal T cells presumably secrete cytokines that promote autoimmune as well as allergic inflammation. (medscape.com)
  • thymus
  • Accordingly, Omenn syndrome is best viewed, not as a specific form of SCID, but rather as an aberrant inflammatory condition that can be associated with multiple genetic abnormalities, which can significantly impair (but not abolish) T-cell development in the thymus. (medscape.com)